 |
|
|
| |
Phase 2 Study of Pegylated Interferon Lambda for HCV: Safety, Viral Response, and Impact of Host Genotype Through Week 12
|
| |
| |
Reported by Jules Levin
21st APASL Conference, Bangkok, Thailand, February 17-20, 2011
Rodriguez-Torres M,1 Lawitz E,2 Ghalib RH,3 Sussman NL,4 Anderson F,5 Everson GT,6 Jacobson IM,7 Lopez-Talavera JC,8 Horga M-A,8 Hillson JL,9 Gray TE,9 Fontana DJ,9 Ramos EL,9 Muir AJ10 1Fundacion de Investigacion de Diego, Santurce, Puerto Rico, USA; 2Alamo Medical Research, San Antonio, TX, USA; 3North Texas Research Institute, Dallas, TX, USA; 4Baylor College of Medicine, Houston, TX, USA; 5Liver and Intestinal Research Centre, Vancouver, BC, Canada; 6University of Colorado Hospital, Aurora, CO, USA; 7Weill Cornell Medical College, New York, NY, USA; 8Bristol-Myers Squibb, Wallingford, CT, USA; 9ZymoGenetics, Inc., Seattle, WA, USA; 10Duke University Medical Center, Durham, NC, USA
|
| |
|
|
|
|
|
